Medhekar R - Search Results

1

Progression-Free Survival of Daratumumab Versus Bortezomib Triplet Combination With Lenalidomide and Dexamethasone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma: TAURUS Chart Review Study.

Gordan LN, Tan CR, Vescio R, Ye JC, Schinke C, Medhekar R, Fu AZ, Lafeuille MH, Thompson-Leduc P, Khare V, Reitan J, Milkovich G, Kaila S, Davies F, Usmani SZ. Gordan LN, et al. Among authors: medhekar r. Clin Lymphoma Myeloma Leuk. 2024 Jan;24(1):55-63. doi: 10.1016/j.clml.2023.09.003. Epub 2023 Sep 14. Clin Lymphoma Myeloma Leuk. 2024. PMID: 37838502 Free article.

2

Patient characteristics associated with dose modifications for VRd among newly diagnosed multiple myeloma patients.

Ran T, Medhekar R, Fu AZ, Patel S, Kaila S. Ran T, et al. Among authors: medhekar r. Future Oncol. 2022 Nov;18(36):3983-3991. doi: 10.2217/fon-2022-0933. Epub 2022 Nov 15. Future Oncol. 2022. PMID: 36377712 Free article.

3

A 3D-Printed Wound-Healing Material Composed of Alginate Dialdehyde-Gelatin Incorporating Astaxanthin and Borate Bioactive Glass Microparticles.

Monavari M, Homaeigohar S, Medhekar R, Nawaz Q, Monavari M, Zheng K, Boccaccini AR. Monavari M, et al. Among authors: medhekar r. ACS Appl Mater Interfaces. 2023 May 8. doi: 10.1021/acsami.2c23252. Online ahead of print. ACS Appl Mater Interfaces. 2023. PMID: 37155412 Review.

4

Survey of patients and physicians on shared decision-making in treatment selection in relapsed/refractory multiple myeloma.

Bylund CL, Eggly S, LeBlanc TW, Kurtin S, Gandee M, Medhekar R, Fu A, Khurana M, Delaney K, Divita A, McNamara M, Baile WF. Bylund CL, et al. Among authors: medhekar r. Transl Behav Med. 2023 Apr 15;13(4):255-267. doi: 10.1093/tbm/ibac099. Transl Behav Med. 2023. PMID: 36688466

5

Real-world patient characteristics and treatment outcomes among nontransplanted multiple myeloma patients who received Bortezomib in combination with Lenalidomide and Dexamethasone as first line of therapy in the United States.

Medhekar R, Ran T, Fu AZ, Patel S, Kaila S. Medhekar R, et al. BMC Cancer. 2022 Aug 18;22(1):901. doi: 10.1186/s12885-022-09980-9. BMC Cancer. 2022. PMID: 35982416 Free PMC article.

6

A 3D Printed Bone Tissue Engineering Scaffold Composed of Alginate Dialdehyde-Gelatine Reinforced by Lysozyme Loaded Cerium Doped Mesoporous Silica-Calcia Nanoparticles.

Monavari M, Medhekar R, Nawaz Q, Monavari M, Fuentes-Chandía M, Homaeigohar S, Boccaccini AR. Monavari M, et al. Among authors: medhekar r. Macromol Biosci. 2022 Sep;22(9):e2200113. doi: 10.1002/mabi.202200113. Epub 2022 Jul 19. Macromol Biosci. 2022. PMID: 35795888

7

Daratumumab Improves Depth of Response and Progression-free Survival in Transplant-ineligible, High-risk, Newly Diagnosed Multiple Myeloma.

Jakubowiak AJ, Kumar S, Medhekar R, Pei H, Lefebvre P, Kaila S, He J, Lafeuille MH, Cortoos A, Londhe A, Mavros P, Lin TS, Usmani SZ. Jakubowiak AJ, et al. Among authors: medhekar r. Oncologist. 2022 Jul 5;27(7):e589-e596. doi: 10.1093/oncolo/oyac067. Oncologist. 2022. PMID: 35462406 Free PMC article.

8

Siegel D, Weisel K, Zahlten-Kumeli A, Medhekar R, Ding B, Leleu X. Siegel D, et al. Among authors: medhekar r. Leuk Lymphoma. 2021 Dec;62(12):3002-3010. doi: 10.1080/10428194.2021.1941927. Epub 2021 Jun 26. Leuk Lymphoma. 2021. PMID: 34180331

9

Real-world evidence for carfilzomib dosing intensity on overall survival and treatment progression in multiple myeloma patients.

Raje N, Medhekar R, Panjabi S, Hines DM, Wang X, Iskander K, Welliver T, Wade RL, Ailawadhi S. Raje N, et al. Among authors: medhekar r. J Oncol Pharm Pract. 2022 Jul;28(5):1130-1139. doi: 10.1177/10781552211015283. Epub 2021 Jun 10. J Oncol Pharm Pract. 2022. PMID: 34111994

10

Cost-effectiveness of once weekly carfilzomib 70 mg/m2 plus dexamethasone in patients with relapsed and refractory multiple myeloma in the United States.

Kumar SK, Majer I, Panjabi S, Medhekar R, Campioni M, Dimopoulos MA. Kumar SK, et al. Among authors: medhekar r. Expert Rev Hematol. 2020 Jun;13(6):687-696. doi: 10.1080/17474086.2020.1746639. Epub 2020 Apr 6. Expert Rev Hematol. 2020. PMID: 32249621

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

24 results

Search Page